Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ticagrelor plus aspirin for long-term prevention of thrombotic events after prior myocardial infarction
NL-OMON39760Phase 3Active, not recruiting
- Sponsor
- AstraZeneca
- Start
- Feb 2011
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of ticagrelor and aspirin in myocardial infarction (MI) and atherothrombosis (3 arms), sponsored by AstraZeneca. Primary endpoint: Primary efficacy endpoint. Started Feb 2011; status: active, not recruiting.
02
Drugs
ticagreloraspirin
03
Conditions
myocardial infarction (MI)atherothrombosis
Beyond the preview
Go deeper on NL-OMON39760.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON39760.